Sheila F Faraj1, Enrico Munari1, Gunes Guner1, Janis Taube1, Robert Anders1, Jessica Hicks1, Alan Meeker1, Mark Schoenberg2, Trinity Bivalacqua2, Charles Drake2, George J Netto3. 1. Department of Pathology, Johns Hopkins University, Baltimore, MD. 2. Department of Urology, Johns Hopkins University, Baltimore, MD; Department of Oncology, Johns Hopkins University, Baltimore, MD. 3. Department of Pathology, Johns Hopkins University, Baltimore, MD; Department of Urology, Johns Hopkins University, Baltimore, MD; Department of Oncology, Johns Hopkins University, Baltimore, MD. Electronic address: gnetto1@jhmi.edu.
Abstract
OBJECTIVE: To evaluate programmed death ligand 1 (PD-L1) expression in urothelial carcinoma of the bladder in relationship with tumor-infiltrating CD8+ T cells. MATERIALS AND METHODS: Tissue microarrays were prepared from 56 cystectomy specimens performed at our hospital (1994-2002). PD-L1 immunoexpression was assessed using the murine antihuman PD-L1 monoclonal antibody 5H1. Extent of membranous PD-L1 expression was assigned in each spot. Spots showing ≥5% expression were considered positive. Average PD-L1 expression per tumor was also calculated (5% positivity cutoff). "High CD8 density" was defined as the presence of ≥60 CD8+ intraepithelial lymphocytes per high power field in a given spot. A tumor was considered high density if ≥50% of its spots were of high density. RESULTS: PD-L1 expression was positive in approximately 20% of tumors. None of the benign urothelium spots expressed PD-L1. High CD8 density was observed in approximately 20% of cases. CD8 density did not correlate with PD-L1 expression. Overall survival (OS) and disease-specific survival (DSS) rates were 14% and 28%, respectively (median follow-up, 31.5 months). PD-L1 expression was associated with age at cystectomy (P = .01). Remaining clinicopathologic parameters were not associated with PD-L1 expression or CD8 density. High CD8 density was associated with favorable OS (P = .02) and DSS (P = .02). The same was true when CD8 density was adjusted for demographic and clinicopathologic parameters. There was no correlation between PD-L1 expression and outcome. CONCLUSION: High intratumoral CD8+ T cell density is associated with better OS and DSS in invasive urothelial carcinoma of the bladder. We found no correlation between PD-L1 expression and outcome.
OBJECTIVE: To evaluate programmed death ligand 1 (PD-L1) expression in urothelial carcinoma of the bladder in relationship with tumor-infiltrating CD8+ T cells. MATERIALS AND METHODS: Tissue microarrays were prepared from 56 cystectomy specimens performed at our hospital (1994-2002). PD-L1 immunoexpression was assessed using the murine antihuman PD-L1 monoclonal antibody 5H1. Extent of membranous PD-L1 expression was assigned in each spot. Spots showing ≥5% expression were considered positive. Average PD-L1 expression per tumor was also calculated (5% positivity cutoff). "High CD8 density" was defined as the presence of ≥60 CD8+ intraepithelial lymphocytes per high power field in a given spot. A tumor was considered high density if ≥50% of its spots were of high density. RESULTS:PD-L1 expression was positive in approximately 20% of tumors. None of the benign urothelium spots expressed PD-L1. High CD8 density was observed in approximately 20% of cases. CD8 density did not correlate with PD-L1 expression. Overall survival (OS) and disease-specific survival (DSS) rates were 14% and 28%, respectively (median follow-up, 31.5 months). PD-L1 expression was associated with age at cystectomy (P = .01). Remaining clinicopathologic parameters were not associated with PD-L1 expression or CD8 density. High CD8 density was associated with favorable OS (P = .02) and DSS (P = .02). The same was true when CD8 density was adjusted for demographic and clinicopathologic parameters. There was no correlation between PD-L1 expression and outcome. CONCLUSION: High intratumoral CD8+ T cell density is associated with better OS and DSS in invasive urothelial carcinoma of the bladder. We found no correlation between PD-L1 expression and outcome.
Authors: Hiroshi Miyamoto; Fadi Brimo; Luciana Schultz; Huihui Ye; Jeremy S Miller; Daniel A Fajardo; Thomas K Lee; Jonathan I Epstein; George J Netto Journal: Arch Pathol Lab Med Date: 2010-08 Impact factor: 5.534
Authors: Alcides Chaux; Sarah Karram; Jeremy S Miller; Daniel A Fajardo; Thomas K Lee; Hiroshi Miyamoto; George J Netto Journal: Hum Pathol Date: 2011-08-04 Impact factor: 3.466
Authors: Stephen A Boorjian; Yuri Sheinin; Paul L Crispen; Sara A Farmer; Christine M Lohse; Susan M Kuntz; Bradley C Leibovich; Eugene D Kwon; Igor Frank Journal: Clin Cancer Res Date: 2008-08-01 Impact factor: 12.531
Authors: Rezaul Karim; Ekaterina S Jordanova; Sytse J Piersma; Gemma G Kenter; Lieping Chen; Judith M Boer; Cornelis J M Melief; Sjoerd H van der Burg Journal: Clin Cancer Res Date: 2009-10-13 Impact factor: 12.531
Authors: Henning Reis; Rene Serrette; Jennifer Posada; Vincent Lu; Ying-Bei Chen; Anuradha Gopalan; Samson W Fine; Satish K Tickoo; Sahussapont J Sirintrapun; Gopa Iyer; Samuel A Funt; Min Yuen Teo; Jonathan E Rosenberg; Dean F Bajorin; Guido Dalbagni; Bernard H Bochner; David B Solit; Victor E Reuter; Hikmat A Al-Ahmadie Journal: Am J Surg Pathol Date: 2019-07 Impact factor: 6.394
Authors: Maria Tretiakova; Regan Fulton; Masha Kocherginsky; Thomas Long; Cigdem Ussakli; Tatjana Antic; Allen Gown Journal: Mod Pathol Date: 2017-12-22 Impact factor: 7.842
Authors: Janis M Taube; Jérôme Galon; Lynette M Sholl; Scott J Rodig; Tricia R Cottrell; Nicolas A Giraldo; Alexander S Baras; Sanjay S Patel; Robert A Anders; David L Rimm; Ashley Cimino-Mathews Journal: Mod Pathol Date: 2017-12-01 Impact factor: 7.842